Department of Medicine, Graduate School of Medicine, University of Tennessee Medical Center, Knoxville, TN, USA.
Adv Ther. 2020 May;37(5):1812-1828. doi: 10.1007/s12325-020-01289-y. Epub 2020 Apr 3.
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) was formed in the late 1990s to spread awareness of chronic obstructive pulmonary disease (COPD) as a major public health problem and facilitate its prevention and treatment. GOLD has since become internationally recognized for the development of evidence-based strategy documents, most notably the annual GOLD Reports, for COPD diagnosis, management, and prevention. The GOLD Reports incorporate the latest evidence and expert consensus to guide the management and prevention of COPD on a global level. Since the first GOLD Report in 2001, profound innovations have taken place regarding inhaler device options, available pharmaceuticals, knowledge regarding effective dosages and potential side effects, and the various combinations of drugs used to relieve symptoms. Concomitantly, an evolution of expert opinion on how best to apply these innovations to the care of patients with COPD has also taken place, an evolution that is nowhere more detailed or definitive than in the 20 years of annual GOLD Reports. We summarize key features and trends in inhalation therapy for stable COPD in these Reports.
全球慢性阻塞性肺疾病倡议(GOLD)成立于 20 世纪 90 年代末,旨在提高人们对慢性阻塞性肺疾病(COPD)这一主要公共卫生问题的认识,并促进其预防和治疗。GOLD 因制定基于循证的策略文件而在国际上得到认可,其中最著名的是年度 GOLD 报告,用于 COPD 的诊断、管理和预防。GOLD 报告结合了最新的证据和专家共识,指导全球范围内 COPD 的管理和预防。自 2001 年第一份 GOLD 报告发布以来,吸入装置选择、现有药物、有效剂量和潜在副作用方面的知识,以及用于缓解症状的各种药物组合方面都取得了重大创新。与此同时,关于如何最好地将这些创新应用于 COPD 患者护理的专家意见也发生了演变,这种演变在每年的 GOLD 报告中比任何其他地方都更加详细和明确。我们总结了这些报告中稳定 COPD 吸入治疗的关键特征和趋势。